The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
979
July 19, 1996
View Complete Issue         Table of Contents 2019 
Dexfenfluramine for Obesity
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dexfenfluramine for Obesity
July 19, 1996 (Issue: 979)
Dexfenfluramine (Redux - Wyeth-Ayerst) has been approved by the US Food and Drug Administration as an aid to diet for treatment of obesity and maintenance of weight loss. Dexfenfluramine is the dextrorotatory isomer of d,l-fenfluramine (Pondimin), ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dexfenfluramine for Obesity
Article code: 979b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.